Vir, GSK begin phase 2/3 trial of VIR-7831 as Covid-19 antibody treatment

This article was originally published here

VIR-7831 is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that is being developed for the early treatment of the viral disease in patients who

The post Vir, GSK begin phase 2/3 trial of VIR-7831 as Covid-19 antibody treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply